In our study, low levels of IL‐7 were associated with poor clinical outcomes of Ld therapy, which may be due to the lower host immune activity of T cells during Len treatment, leading to shorter OS in patients with MM who received Ld therapy. The gene discussed is IL7; the disease is Miyoshi myopathy.